...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

BREAKING:  Hollister Biosciences Provides Update on Q2 2020, Generated Record Quarterly Revenue of CDN$ 11.5 Million

  • CDN$ 1.375 million in EBITDA
  • Bureau of Cannabis Control officially renewed its cannabis distribution license for the next year through August 2021
  • "We are very pleased with our revenue growth year to date.  Sales of cannabis related products have proven to be resilient throughout the COVID-19 pandemic.  We hope to continue to deliver strong results as the year progresses" stated Carl Saling, CEO.

Hollister large

Hub On AGORACOM / Read Release

Message: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019

The choice of the word « improves » in the title is interesting. Does it mean cognitive function was better at the end of the trial than at the start, or only that the rate of decline was reduced (so that at the end of the trial CF was better in the ABL group than in the placebo group, but still lower than at baseline).

Either result would be very good, of course, but the former would be a dream. Here’s hoping!

 

Share
New Message
Please login to post a reply